Literature DB >> 6775652

Monoclonal immunoglobulin light chains in urine of patients with lymphoma.

J Pierson, T Darley, G T Stevenson, M Virji.   

Abstract

Fourteen of 31 patients with non-Hodgkin's lymphoma or chronic lymphocytic leukaemia had a monoclonal immunoglobulin light chain detectable in their urine. These chains are believed to be synthesized by the B lymphoid cells comprising the tumour. Upon comparing the different cases, the occurrence and amount of monoclonal light chain showed no dependence upon the extent of tumour, the presence of leukaemic component, or exposure to cytotoxic therapy. The method of detection involved purifying the urinary light chains by immunosorption, and examining their electrophoretic distributions so as to distinguish between the homogeneous monoclonal chains and their heterogeneous normal analogues.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6775652      PMCID: PMC2010299          DOI: 10.1038/bjc.1980.129

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Urinary light-chain excretionin myeloma and other disorders--an evaluation of the Bence-Jones test.

Authors:  F D Lindström; R C Williams; W R Swaim; E F Freier
Journal:  J Lab Clin Med       Date:  1968-05

2.  Specific dimerization of the light chains of human immunoglobulin.

Authors:  G T Stevenson; D Straus
Journal:  Biochem J       Date:  1968-07       Impact factor: 3.857

3.  Melphalan therapy for plasma cell myeloma.

Authors:  R Alexanian; D E Bergsagel; P J Migliore; W K Vaughn; C D Howe
Journal:  Blood       Date:  1968-01       Impact factor: 22.113

4.  New approaches to the classification of the lymphomata.

Authors:  R J Lukes; R D Collins
Journal:  Br J Cancer Suppl       Date:  1975-03

5.  The 24-hour excretion of plasma proteins in the urine of apparently healthy subjects.

Authors:  L Hemmingsen; P Skaarup
Journal:  Scand J Clin Lab Invest       Date:  1975-07       Impact factor: 1.713

6.  Hypervariable regions, idiotypy, and the antibody-combining site.

Authors:  J D Capra; J M Kehoe
Journal:  Adv Immunol       Date:  1975       Impact factor: 3.543

7.  The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia.

Authors:  T A Waldmann; W Strober; R P Mogielnicki
Journal:  J Clin Invest       Date:  1972-08       Impact factor: 14.808

8.  The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments.

Authors:  R D Wochner; W Strober; T A Waldmann
Journal:  J Exp Med       Date:  1967-08-01       Impact factor: 14.307

9.  Immunoglobulins on the surface of lymphocytes. IV. Distribution in hypogammaglobulinemia, cellular immune deficiency, and chronic lymphatic leukemia.

Authors:  H M Grey; E Rabellino; B Pirofsky
Journal:  J Clin Invest       Date:  1971-11       Impact factor: 14.808

10.  One cell-one immunoglobulin. Origin of limited heterogeneity of myeloma proteins.

Authors:  Z L Awdeh; A R Williamson; B A Askonas
Journal:  Biochem J       Date:  1970-01       Impact factor: 3.857

View more
  4 in total

1.  Urinary monoclonal free light chains in primary Sjögren's syndrome: an aid to the diagnosis of malignant lymphoma.

Authors:  M T Walters; F K Stevenson; A Herbert; M I Cawley; J L Smith
Journal:  Ann Rheum Dis       Date:  1986-03       Impact factor: 19.103

Review 2.  Treatment of lymphoid tumors with anti-idiotype antibodies.

Authors:  G T Stevenson; F K Stevenson
Journal:  Springer Semin Immunopathol       Date:  1983

3.  Mitogen-induced maturation of chronic lymphocytic leukemia B lymphocytes.

Authors:  P Guglielmi; J L Preud'homme; R Ciorbaru-Barot; M Seligmann
Journal:  J Clin Immunol       Date:  1982-07       Impact factor: 8.317

4.  Monoclonal immunoglobulin light chain in urine of patients with B lymphocytic disease: its source and use as a diagnostic aid.

Authors:  F K Stevenson; M Spellerberg; J L Smith
Journal:  Br J Cancer       Date:  1983-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.